Thus, activation of hypothalamic dopaminergic neurotransmission by dopamine agonists can reduce incidence and prevalence of MetS in patients with hyperprolactinaemia by controlling of PRL release and improving of insulin sensitivity.88 This evidence concerns the gene PRL and hyperprolactinemia.